ALTH Allos Therapeutics, Inc. (MM)

Allos Therapeutics To Hold Third Quarter 2004 Financial Results Conference Call and Webcast on Tuesday, November 9 WESTMINSTER, Colo., Nov. 4 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) will hold a conference call Tuesday, November 9, 2004, at 11:00 AM ET to discuss its third quarter 2004 financial results. Time: 11:00 AM ET Date: Tuesday, November 9, 2004 Dial-in: (877) 407-8031 Domestic / (201) 689-8031 International Participant code: 123530 Webcast: http://www.allos.com/ (homepage and investor relations section) Interested parties unable to participate in the live conference call may access a recorded rebroadcast by dialing 877-660-6853 (domestic) or +1-201-612-7415 (international); the pass code number is 123530. The replay will be available from 1:00 PM ET on Tuesday, November 9, 2004 until 11:59 PM ET on November 16, 2004. In addition, the webcast will be archived for 30 days at http://www.allos.com/ . Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The company's lead clinical candidate, EFAPROXYN(TM), is a synthetic small molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and enhance the efficacy of standard radiation therapy. In addition, Allos is developing PDX (pralatrexate), a novel small molecule cytoxic injectable antifolate (DHFR inhibitor) that is currently being investigated in patients with non-small cell lung cancer and non- Hodgkin's lymphoma. For more information, please visit the company's web site at: http://www.allos.com/ . DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer Neiman, (media) Corporate Communications of Allos Therapeutics, Inc., +1-720-540-5227, Web site: http://www.allos.com/

Copyright